Literature DB >> 20151995

Benefits of moderate weight loss in patients with type 2 diabetes.

Ken Fujioka1.   

Abstract

Weight loss is a primary goal of therapy in overweight patients with type 2 diabetes. This review examines whether positive patient outcomes are observed even after relatively small amounts of weight loss, that is, weight loss being more easily attainable in practice. Clinical studies demonstrate that therapeutic benefit rises with increasing weight loss, but that losses as low as 0.45-4 kg (1-9 lb) have positive effects on metabolic control, cardiovascular risk factors and mortality rates. Even the intention to lose weight, without significant success, can improve outcomes in patients with diabetes, presumably because of the healthy behaviours associated with the attempt. The current data support a continued focus on weight loss, including moderate weight loss, as a key component of good care for overweight patients with type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20151995     DOI: 10.1111/j.1463-1326.2009.01155.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  12 in total

1.  Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study.

Authors:  Scott A Shikora; James Toouli; Miguel F Herrera; Bård Kulseng; Roy Brancatisano; Lilian Kow; Juan P Pantoja; Gjermund Johnsen; Anthony Brancatisano; Katherine S Tweden; Mark B Knudson; Charles J Billington; Charles J Billingto
Journal:  Obes Surg       Date:  2016-05       Impact factor: 4.129

2.  The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy.

Authors:  K Fujioka; R Plodkowski; P M O'Neil; K Gilder; B Walsh; F L Greenway
Journal:  Int J Obes (Lond)       Date:  2016-06-22       Impact factor: 5.095

Review 3.  Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.

Authors:  Sandra J Hamilton; Gerald F Watts
Journal:  Rev Diabet Stud       Date:  2013-08-10

4.  Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions.

Authors:  Jorge R Miranda-Massari; José R Rodríguez-Gómez; Michael J González; Carlos Cidre; Jorge Duconge; Heriberto Marín; Kazuko Grace; Howard L McLeod
Journal:  Int J Diabetes Res       Date:  2016

Review 5.  Pharmacist interventions to improve cardiovascular disease risk factors in diabetes: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Valérie Santschi; Arnaud Chiolero; Gilles Paradis; April L Colosimo; Bernard Burnand
Journal:  Diabetes Care       Date:  2012-12       Impact factor: 19.112

6.  Effect of the Obesity Epidemic on Kidney Transplantation: Obesity Is Independent of Diabetes as a Risk Factor for Adverse Renal Transplant Outcomes.

Authors:  Jennifer M Kwan; Zahraa Hajjiri; Ahmed Metwally; Patricia W Finn; David L Perkins
Journal:  PLoS One       Date:  2016-11-16       Impact factor: 3.240

7.  The influence of dopamine-beta-hydroxylase and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with type 2 diabetes mellitus.

Authors:  Nela Pivac; Fran Borovecki; Tomislav Bozek; Antonela Blazekovic; Matea Nikolac Perkovic; Kristina Gotovac Jercic; Aleksandra Sustar; Lea Smircic-Duvnjak; Tiago F Outeiro
Journal:  Diabetol Metab Syndr       Date:  2017-12-04       Impact factor: 3.320

8.  A call to action to inform patient-centred approaches to obesity management: Development of a disease-illness model.

Authors:  John Fastenau; Ronette L Kolotkin; Ken Fujioka; Maria Alba; William Canovatchel; Shana Traina
Journal:  Clin Obes       Date:  2019-04-11

9.  Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus.

Authors:  S Shikora; J Toouli; M F Herrera; B Kulseng; H Zulewski; R Brancatisano; L Kow; J P Pantoja; G Johnsen; A Brancatisano; K S Tweden; M B Knudson; C J Billington
Journal:  J Obes       Date:  2013-07-30

Review 10.  GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

Authors:  S Brunton
Journal:  Int J Clin Pract       Date:  2014-02-06       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.